Stock 603087 GAN & LEE PHARMACEUTICALS.
Add to a list
To use this feature you must be a member
Log inSign up

Company Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-04-25 EDT 		5-day change 1st Jan Change
48.77 CNY +1.60% Intraday chart for Gan & Lee Pharmaceuticals. +16.34% -7.37%
04-24 Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-24 Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Number of employees: 4,057

Sales per Business

CNY in Million2022Weight2023Weight Delta
Biological Products
90.5 %
1,485 86.7 % 2,360 90.5 % +58.98%
Medical Equipment and Others
5.7 %
93 5.4 % 148 5.7 % +60.45%
Franchise Service
3.8 %
135 7.9 % 99 3.8 % -26.48%

Sales per region

CNY in Million2022Weight2023Weight Delta
China
83.7 %
1,436 83.9 % 2,182 83.7 % +51.93%
International
16.3 %
276 16.1 % 426 16.3 % +54.29%

Managers

Managers TitleAgeSince
Kai Du CEO
 Chief Executive Officer 47 07-12-31
Zhong Ru Gan FOU
 Founder 76 98-06-16
Tao Zhang CHM
 Chairman 46 04-12-31
Wei Chen BRD
 Director/Board Member 44 18-12-31
Yi Wang BRD
 Director/Board Member 34 16-11-30
Wei Qiang Song BRD
 Director/Board Member 42 04-12-31
Rong Zou SEC
 Corporate Secretary 41 06-12-31

Members of the board

Members of the board TitleAgeSince
Zhong Ru Gan FOU
 Founder 76 98-06-16
Kai Du CEO
 Chief Executive Officer 47 07-12-31
Wei Qiang Song BRD
 Director/Board Member 42 04-12-31
Yan Qing He BRD
 Director/Board Member 39 19-04-25
Guo Jun Zheng BRD
 Director/Board Member 56 19-04-25
Jia Xin Wang BRD
 Director/Board Member 31 14-12-31
Lei Yin BRD
 Director/Board Member 45 21-03-17
Jiao Jiao BRD
 Director/Board Member 36 21-03-17
Yi Wang BRD
 Director/Board Member 34 16-11-30
Wei Chen BRD
 Director/Board Member 44 18-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 594,161,750 285,308,855 ( 48.02 %) 4,113,200 ( 0.6923 %) 48.02 %

Shareholders

NameEquities%Valuation
Zhong Ru Gan
33.35 %
177,135,207 33.35 % 982 M ¥
Qiming Venture Partners Ltd.
5.594 %
29,708,087 5.594 % 165 M ¥
Boyu Capital Advisory Co. Ltd.
3.322 %
17,643,473 3.322 % 98 M ¥
THE GOLDMAN SACHS GROUP, INC.
1.581 %
8,397,341 1.581 % 47 M ¥
Xi Ru Gan
1.172 %
6,223,276 1.172 % 35 M ¥
Da Cheng Fund Management Co., Ltd.
1.152 %
6,118,701 1.152 % 34 M ¥
China Southern Asset Management Co., Ltd.
1.111 %
5,898,166 1.111 % 33 M ¥
China Merchants Fund Management Co., Ltd.
0.8875 %
4,713,100 0.8875 % 26 M ¥
Guotai Asset Management Co., Ltd.
0.3549 %
1,884,731 0.3549 % 10 M ¥
Tian Hong Asset Management Co., Ltd.
0.2505 %
1,330,566 0.2505 % 7 M ¥
NameEquities%Valuation
Zhong Ru Gan
45.19 %
28,508,550 45.19 % 158 M ¥
Qiming Venture Partners Ltd.
25.16 %
15,875,800 25.16 % 88 M ¥
Boyu Capital Advisory Co. Ltd.
9.159 %
5,777,913 9.159 % 32 M ¥
Hillhouse Investment Management Ltd. (Invest)
6.810 %
4,296,032 6.810 % 24 M ¥
CITIC LIMITED
6.746 %
4,256,033 6.746 % 24 M ¥

Company contact information

Gan & Lee Pharmaceuticals Co., Ltd.

8 Nanfeng West 1st Road Miao County Town

101109, Beijing

+

http://www.ganlee.com
address Gan & Lee Pharmaceuticals.(603087)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Sales per region

Ratings for Gan & Lee Pharmaceuticals.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
48.77 CNY
Average target price
58 CNY
Spread / Average Target
+18.93%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
GAN & LEE PHARMACEUTICALS. Stock Gan & Lee Pharmaceuticals.
-7.37% 3.97B
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 603087 Stock
  4. Company Gan & Lee Pharmaceuticals.